FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturingFierceMedicalDevices

Free Newsletter

About | View Sample | Privacy
Related Topics >> Cervarix | Vaccine | GlaxoSmithKline

Glaxo ready to wait for late-stage Cervarix data

Tools

GlaxoSmithKline now says it will wait for the completion of a late-stage trial of its cervical cancer vaccine Cervarix before answering the FDA's questions about the therapy. That will push back any approval of Cervarix until 2010, at the earliest. And it confirms some of the worst fears of market analysts, who see Merck's Gardasil gobbling up the market long before Cervarix arrives on the scene.

The long-term efficacy trial that GSK is waiting on tracks the real-world experiences of girls and young women who have been vaccinated. The cancer vaccine is on sale in 67 countries.

- read the report in the Financial Times

Related Articles:
Glaxo's Cervarix delayed until late 2009
GSK hit with Cervarix application delay
U.K. health officials in cancer vaccine fight
France picks Gardasil over GSK upstart


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Cervarix   Vaccine   GlaxoSmithKline  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.